These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

557 related items for PubMed ID: 17483341

  • 1. The Akt/mammalian target of rapamycin signal transduction pathway is activated in high-risk myelodysplastic syndromes and influences cell survival and proliferation.
    Follo MY, Mongiorgi S, Bosi C, Cappellini A, Finelli C, Chiarini F, Papa V, Libra M, Martinelli G, Cocco L, Martelli AM.
    Cancer Res; 2007 May 01; 67(9):4287-94. PubMed ID: 17483341
    [Abstract] [Full Text] [Related]

  • 2. Acetaldehyde promotes rapamycin-dependent activation of p70(S6K) and glucose uptake despite inhibition of Akt and mTOR in dopaminergic SH-SY5Y human neuroblastoma cells.
    Fang CX, Yang X, Sreejayan N, Ren J.
    Exp Neurol; 2007 Jan 01; 203(1):196-204. PubMed ID: 16962100
    [Abstract] [Full Text] [Related]

  • 3. Activation of mammalian target of rapamycin signaling promotes cell cycle progression and protects cells from apoptosis in mantle cell lymphoma.
    Peponi E, Drakos E, Reyes G, Leventaki V, Rassidakis GZ, Medeiros LJ.
    Am J Pathol; 2006 Dec 01; 169(6):2171-80. PubMed ID: 17148679
    [Abstract] [Full Text] [Related]

  • 4. Mammalian target of rapamycin, a molecular target in squamous cell carcinomas of the head and neck.
    Amornphimoltham P, Patel V, Sodhi A, Nikitakis NG, Sauk JJ, Sausville EA, Molinolo AA, Gutkind JS.
    Cancer Res; 2005 Nov 01; 65(21):9953-61. PubMed ID: 16267020
    [Abstract] [Full Text] [Related]

  • 5. Involvement of the Akt/mTOR pathway on EGF-induced cell transformation.
    Nomura M, He Z, Koyama I, Ma WY, Miyamoto K, Dong Z.
    Mol Carcinog; 2003 Sep 01; 38(1):25-32. PubMed ID: 12949840
    [Abstract] [Full Text] [Related]

  • 6. Rapamycin inhibits cell motility by suppression of mTOR-mediated S6K1 and 4E-BP1 pathways.
    Liu L, Li F, Cardelli JA, Martin KA, Blenis J, Huang S.
    Oncogene; 2006 Nov 09; 25(53):7029-40. PubMed ID: 16715128
    [Abstract] [Full Text] [Related]

  • 7. Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies.
    Yee KW, Zeng Z, Konopleva M, Verstovsek S, Ravandi F, Ferrajoli A, Thomas D, Wierda W, Apostolidou E, Albitar M, O'Brien S, Andreeff M, Giles FJ.
    Clin Cancer Res; 2006 Sep 01; 12(17):5165-73. PubMed ID: 16951235
    [Abstract] [Full Text] [Related]

  • 8. Critical and diverse involvement of Akt/mammalian target of rapamycin signaling in human lung carcinomas.
    Dobashi Y, Suzuki S, Matsubara H, Kimura M, Endo S, Ooi A.
    Cancer; 2009 Jan 01; 115(1):107-18. PubMed ID: 19090006
    [Abstract] [Full Text] [Related]

  • 9. Novel pathway in Bcr-Abl signal transduction involves Akt-independent, PLC-gamma1-driven activation of mTOR/p70S6-kinase pathway.
    Markova B, Albers C, Breitenbuecher F, Melo JV, Brümmendorf TH, Heidel F, Lipka D, Duyster J, Huber C, Fischer T.
    Oncogene; 2010 Feb 04; 29(5):739-51. PubMed ID: 19881535
    [Abstract] [Full Text] [Related]

  • 10. Morphoproteomic and molecular concomitants of an overexpressed and activated mTOR pathway in renal cell carcinomas.
    Lin F, Zhang PL, Yang XJ, Prichard JW, Lun M, Brown RE.
    Ann Clin Lab Sci; 2006 Feb 04; 36(3):283-93. PubMed ID: 16951269
    [Abstract] [Full Text] [Related]

  • 11. Silibinin inhibits hypoxia-inducible factor-1alpha and mTOR/p70S6K/4E-BP1 signalling pathway in human cervical and hepatoma cancer cells: implications for anticancer therapy.
    García-Maceira P, Mateo J.
    Oncogene; 2009 Jan 22; 28(3):313-24. PubMed ID: 18978810
    [Abstract] [Full Text] [Related]

  • 12. Combined treatment with cisplatin and sirolimus to enhance cell death in human mesothelioma.
    Hartman ML, Esposito JM, Yeap BY, Sugarbaker DJ.
    J Thorac Cardiovasc Surg; 2010 May 22; 139(5):1233-40. PubMed ID: 19853261
    [Abstract] [Full Text] [Related]

  • 13. Survival signaling by Notch1: mammalian target of rapamycin (mTOR)-dependent inhibition of p53.
    Mungamuri SK, Yang X, Thor AD, Somasundaram K.
    Cancer Res; 2006 May 01; 66(9):4715-24. PubMed ID: 16651424
    [Abstract] [Full Text] [Related]

  • 14. Mammalian target of rapamycin is required for thrombopoietin-induced proliferation of megakaryocyte progenitors.
    Drayer AL, Olthof SG, Vellenga E.
    Stem Cells; 2006 Jan 01; 24(1):105-14. PubMed ID: 16123382
    [Abstract] [Full Text] [Related]

  • 15. Phosphorylation of ribosomal p70 S6 kinase and rapamycin sensitivity in human colorectal cancer.
    Nozawa H, Watanabe T, Nagawa H.
    Cancer Lett; 2007 Jun 18; 251(1):105-13. PubMed ID: 17175097
    [Abstract] [Full Text] [Related]

  • 16. Immunohistochemical analysis of the mammalian target of rapamycin signalling pathway in extramammary Paget's disease.
    Chen S, Nakahara T, Uchi H, Takeuchi S, Takahara M, Kido M, Dugu L, Tu Y, Moroi Y, Furue M.
    Br J Dermatol; 2009 Aug 18; 161(2):357-63. PubMed ID: 19438435
    [Abstract] [Full Text] [Related]

  • 17. In human endothelial cells amino acids inhibit insulin-induced Akt and ERK1/2 phosphorylation by an mTOR-dependent mechanism.
    Pellegatta F, Catapano AL, Luzi L, Terruzzi I.
    J Cardiovasc Pharmacol; 2006 May 18; 47(5):643-9. PubMed ID: 16775502
    [Abstract] [Full Text] [Related]

  • 18. IGF-1-stimulated protein synthesis in oligodendrocyte progenitors requires PI3K/mTOR/Akt and MEK/ERK pathways.
    Bibollet-Bahena O, Almazan G.
    J Neurochem; 2009 Jun 18; 109(5):1440-51. PubMed ID: 19453943
    [Abstract] [Full Text] [Related]

  • 19. Overexpressed eIF4E is functionally active in surgical margins of head and neck cancer patients via activation of the Akt/mammalian target of rapamycin pathway.
    Nathan CO, Amirghahari N, Abreo F, Rong X, Caldito G, Jones ML, Zhou H, Smith M, Kimberly D, Glass J.
    Clin Cancer Res; 2004 Sep 01; 10(17):5820-7. PubMed ID: 15355912
    [Abstract] [Full Text] [Related]

  • 20. Androgens induce prostate cancer cell proliferation through mammalian target of rapamycin activation and post-transcriptional increases in cyclin D proteins.
    Xu Y, Chen SY, Ross KN, Balk SP.
    Cancer Res; 2006 Aug 01; 66(15):7783-92. PubMed ID: 16885382
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.